Production (Stage)
Emmaus Life Sciences, Inc.
EMMA
$0.017
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.41M | 3.29M | 5.48M | 5.38M | 2.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.41M | 3.29M | 5.48M | 5.38M | 2.51M |
| Cost of Revenue | 225.00K | 309.00K | 394.00K | 241.00K | 257.00K |
| Gross Profit | 2.18M | 2.98M | 5.08M | 5.14M | 2.25M |
| SG&A Expenses | 2.99M | 3.40M | 4.12M | 4.36M | 4.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.39M | 3.85M | 4.66M | 4.80M | 5.25M |
| Operating Income | -980.00K | -557.00K | 821.00K | 582.00K | -2.74M |
| Income Before Tax | -2.33M | -1.74M | 1.83M | -2.15M | -4.36M |
| Income Tax Expenses | 4.00K | 6.00K | -1.00K | 31.00K | -7.00K |
| Earnings from Continuing Operations | -2.33M | -1.75M | 1.83M | -2.18M | -4.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.33M | -1.75M | 1.83M | -2.18M | -4.35M |
| EBIT | -980.00K | -557.00K | 821.00K | 582.00K | -2.74M |
| EBITDA | -975.00K | -552.00K | 826.00K | 588.00K | -2.73M |
| EPS Basic | -0.04 | -0.03 | 0.03 | -0.03 | -0.07 |
| Normalized Basic EPS | -0.02 | -0.02 | 0.02 | -0.02 | -0.05 |
| EPS Diluted | -0.04 | -0.03 | 0.01 | -0.03 | -0.07 |
| Normalized Diluted EPS | -0.02 | -0.02 | 0.01 | -0.02 | -0.05 |
| Average Basic Shares Outstanding | 63.87M | 63.86M | 63.87M | 63.36M | 61.85M |
| Average Diluted Shares Outstanding | 63.87M | 63.86M | 162.73M | 63.36M | 61.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |